Antibodies selected from our libraries have high affinities and developability properties, as good as, or better, than clinical antibodies on the market, saving you time and money during development.
We use our in-house libraries, integrated selection pipeline, next generation sequencing and AbXtract to generate unusually diverse, high affinity, drug-like developable antibodies.
60% of antibodies selected directly from our Generation 3 libraries have affinities below 10nM; 20% have affinities in the subnanomolar range; and our best affinity antibody to date is 13 pM.
After selection we use the machine learning module of AbXtract to group selected antibodies into as many as 1,000 distinctive cluster, providing antibodies against a wide variety of target epitopes.
Over 80% of antibodies from our Generation 3 Platform have no measurable biophysical liabilities, with all tested to date behaving as well as, or better, than the best therapeutic antibodies.
Full Platform Transfer
To empower discover at your site, we equip you with our integrated, state-of-the-art, antibody discovery platform, including exclusive libraries, vectors, protocols and extensive training.
All our libraries are provided as exclusive assets, with HCDR3 donors used once and other CDRs reassembled for each library, making the antibody diversity your alone to mine, and not shared with others.
Your exclusive HCDR3 diversity can be used to build more than one library format, providing access to different antibody functionalities.
Collaborate & Customize
In addition, to in-house designs, we create custom libraries, modifying scaffolds, tags, vectors or excluded libraries. When you need more hands, let us also conduct discovery using your exclusive library.
Our terms eliminate complexities typically seen in platform transfers. We recognize each company is unique, and have successfully tailored structures to meet each partner’s needs.